首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer.
【24h】

Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer.

机译:3D-CT测量在食管癌患者中放化疗早期反应评估中的准确性和可重复性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Chemoradiotherapy is increasingly applied in patients with oesophageal cancer. The aim of the present study was to determine whether 3D-CT volumetry is able to differentiate between responding and non-responding oesophageal tumours early in the course of neoadjuvant chemoradiotherapy. PATIENTS AND METHODS: Serial CT before and after two weeks of neoadjuvant chemoradiotherapy was performed in the multimodality treatment arm of a randomised trial including patients with oesophageal carcinoma. CT response was measured with the change in tumour volume between baseline and after 14 days of neoadjuvant therapy. Receiver Operating Characteristic (ROC) analysis was used to evaluate the ability of 3D-CT as an early imaging marker of response. RESULTS: CT response analysis was performed in 39 patients, of whom 26 patients were histopathological responders. Median tumour volume increased between baseline and after 14 days of chemoradiotherapy in histopathological responders as well as in non-responders, though changes were not statistically significant. The area under the ROC curve was 0.71. CONCLUSION: Tumour volume changes after 14 days of neoadjuvant chemoradiotherapy as measured by 3D-CT were not associated with histopathological tumour response. CT volumetry should not be used for early response assessment in patients with potentially curable oesophageal cancer treated with neoadjuvant chemoradiotherapy.
机译:背景:放化疗已越来越多地应用于食道癌患者。本研究的目的是确定3D-CT容量测定法在新辅助放化疗过程中是否能够早期区分反应性和非反应性食管肿瘤。患者和方法:在一项包括食道癌患者在内的随机试验的多模式治疗组中,在新辅助放化疗前后两周进行了串联CT。用基线和新辅助治疗14天后肿瘤体积的变化测量CT反应。接收者操作特征(ROC)分析用于评估3D-CT作为早期反应成像标志物的能力。结果:39例患者进行了CT反应分析,其中26例为组织病理学反应者。在基线和化学放疗14天后之间,在组织病理学应答者和无应答者中,肿瘤体积增加,尽管变化在统计学上不显着。 ROC曲线下的面积为0.71。结论:3D-CT测量的新辅助放化疗14天后的肿瘤体积变化与组织病理学肿瘤反应无关。对于使用新辅助放化疗治疗的潜在可治愈的食道癌患者,不应将CT容量计用于早期反应评估。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号